The Pharma Letter |
Asthma market to remain stable over next decade, despite generic erosion
The Pharma Letter New market potential in underserved asthma population: Emerging anticytokines that are predicted to launch during the next decade will serve part of the unmet need in the severe, refractory asthma population, which is currently served by only systemic … |
View full post on asthma – Google News